Fennec pharmaceuticals inc. (FENC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating activities:
Net loss

-12,775

-9,888

-7,046

-2,789

-659

-2,176

1,845

-5,163

4,685

Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized (gain)/loss on derivatives

0

167

-134

48

1,237

355

3,777

-

-

Amortization of deferred issuance cost

64

0

-

-

-

-

-

-

-

Gain on derivative settlement

-

-

-

-

-

349

0

-1,563

8,071

Depreciation and amortization

-

-

-

-

-

-

-

0

0

Non-cash settlement of Cadherin litigation

-

-

-

-

-

-

-

0

0

Unrealized foreign exchange loss

-

-

-

-

-

-

-

0

9

Loss on impairment of capital assets

-

-

-

-

-

-

-

0

0

Amortization of deferred lease inducements

-

-

-

-

-

-

-

0

0

Non-cash severance

-

-

-

-

-

-

-

0

-

Non-cash severance expense

-

-

-

-

-

-

-

-

0

Stock-based compensation - contractors

417

272

741

88

0

434

25

152

121

Stock-based compensation - employees

2,665

1,825

1,517

615

97

627

62

174

129

Changes in operating assets and liabilities:
Prepaid assets

58

40

85

-33

28

-33

-

-

-

Other assets

7

-12

10

2

-16

9

-

-

-

Accounts payable

580

177

611

-54

-11

96

-

-

-

Accrued liabilities

54

-17

497

33

-40

0

-

-

-

Net cash used in operating activities

-

-

-

-

-1,862

-1,699

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

0

0

Changes in operating assets and liabilities

-

-

-

-

-

-

365

-280

81

Net cash used in operating activities

-9,060

-7,826

-3,641

-2,124

-

-

-2,210

-2,994

-3,226

Purchase of capital assets

-

-

-

-

-

-

-

0

0

Disposal of capital assets

-

-

-

-

-

-

-

0

0

Proceeds from sale of assets

-

-

-

-

-

-

-

0

0

Release of restricted cash

-

-

-

-

-

-

-

0

0

Restricted cash

-

-

-

-

-

-

-

0

0

Purchase of short-term investments

-

-

-

-

-

-

-

0

0

Redemption of short-term investments

-

-

-

-

-

-

-

0

0

Investment in Cadherin Biomedical Inc.

-

-

-

-

-

-

-

0

0

Acquired intellectual property rights

-

-

-

-

-

-

-

0

0

Net cash used in investing activity

-

-

0

0

-

-

0

0

0

Financing activities:
Net cash used in investing activity

-

-

-

-

0

0

-

-

-

Cash paid for issuance costs

71

0

-

-

-

-

-

0

0

Conversion of long-term debt to equity

-

-

-

-

-

-

-

0

0

Long-term debt repayment

-

-

-

-

-

-

-

0

0

Capital lease repayments

-

-

-

-

-

-

-

0

0

Issuance of shares, net of issuance costs

-

-

27,381

5,000

0

2,182

1,570

0

2,566

Short swing profit judgment offset with settlement expense

0

18

0

-

-

-

-

-

-

Financing expenses

-

-

-

-

-

-

-

0

0

Proceeds from convertible note

-

-

-

-

-

-

-

0

0

Other liability repayments

-

-

-

-

-

-

-

0

0

Security deposits received

-

-

-

-

-

-

-

0

0

Issuance of shares, options exercise

0

210

563

6

48

140

0

0

0

Issuance of shares, warrants exercise

0

2,119

31

102

449

21

0

-

-

Net cash provided by financing activities

-

-

-

-

497

2,343

-

-

-

Net cash used in financing activities

-71

2,347

27,975

5,108

-

-

1,570

0

2,566

Decrease in cash and cash equivalents

-9,131

-5,479

-

-

-

-

-

-

-

Effect of exchange rate on cash and cash equivalents

-

-

-

-

0

0

0

0

10

Decrease in cash and cash equivalents

-

-

24,334

2,984

-1,365

644

-640

-2,994

-650

Supplemental non-cash disclosure:
Non-cash deferred issuance cost (warrant value)

255

0

-

-

-

-

-

-

-